Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase.
The current study was undertaken to examine whether we can target adenylyl cyclase to regulate beta-adrenergic signaling with increased cardiac selectivity. Forskolin, a natural diterpene compound, interacts directly with adenylyl cyclase. We studied the adenylyl cyclase isoform-selectivity of forskolin derivatives using insect cell membranes overexpressing type II, III, and V adenylyl cyclase isoforms. 6-[3-(dimethylamino) propionyl] forskolin (NKH477) stimulated type V more potently (1.87 +/- 0.02-fold) than type II (1.04 +/- 0.02-fold) and type III (0.89 +/- 0.03-fold) relative to forskolin (50 microM, P < 0.05). Similarly, 6-[3-(dimethylamino)propionyl]-14,15-dihydro-forskolin (DMAPD) stimulated type V (1.39 +/- 0.02-fold) more potently than types II (0.66 +/- 0.02-fold) and type III (0.31 +/- 0.02-fold) relative to forskolin (P < 0.05). This selectivity was maintained under different assay conditions--i.e. with different forskolin (0.1-100 microM) and Mg (1-10 mM) concentrations, with or without Gs alpha. NKH477 increased cAMP accumulation in HEK293 cells stably overexpressing type V more than forskolin (1.57 +/- 0.13-fold) (P < 0.05). Examination of multiple tissue homogenates revealed that DMAPD and NKH477 stimulated cardiac adenylyl cyclase more potently than the other tissue adenylyl cyclases (lung, brain, and kidney) relative to forskolin. Our results suggest that a particular side-chain modification of forskolin enhanced the selectivity for the cardiac isoform stimulation. Adenylyl cyclase isoforms may be targeted to increase tissue selectivity in future drug therapy for beta-adrenergic regulation.